HR+/HER2- LOBULAR BREAST CANCER (BC)

Clinical trials for HR+/HER2- LOBULAR BREAST CANCER (BC) explained in plain language.

Never miss a new study

Get alerted when new HR+/HER2- LOBULAR BREAST CANCER (BC) trials appear

Sign up with your email to follow new studies for HR+/HER2- LOBULAR BREAST CANCER (BC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New PET tracers could sharpen cancer detection

Diagnosis Recruiting now

This early-phase study is testing two new radioactive imaging agents (JFI447 and FFG233) to see how well they light up different solid tumors on PET scans. About 66 adults with advanced cancers like pancreatic, lung, breast, colorectal, or sarcoma will receive the agents and unde…

Matched conditions: HR+/HER2- LOBULAR BREAST CANCER (BC)

Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Diagnosis

Last updated Jun 15, 2026 19:07 UTC

HR+/HER2- LOBULAR BREAST CANCER (BC)

Get alerted when new HR+/HER2- LOBULAR BREAST CANCER (BC) trials appear

New PET tracers could sharpen cancer detection